索拉非尼治疗肝细胞肝癌耐药机制的研究进展

Advances in the study of sorafenib in the treatment of hepatocellular carcinoma drug resistance mechanism

肝细胞肝癌(Hepatocellular carcinoma,HCC)是最常见的原发性肝癌,由于疾病早期诊断困难、病情进展快、治疗选择有限等原因导致HCC患者预后差,给患者的生命安全造成严重威胁。索拉非尼是一种小分子多激酶抑制剂,是目前唯一被批准用来治疗晚期HCC的靶向药物。但是,往往因为耐药性的产生导致治疗失败。HCC包括原发性和获得性对于索拉非尼治疗耐药性的产生具体机制尚不明确。因此,了解索拉非尼治疗HCC患者耐药性产生的机制,并提出更有效的治疗策略显得尤为重要。

Hepatocellular carcinoma(HCC)is the most common primary liver cancer.Due to the difficulty in early diag⁃nosis,rapid progression of the disease and limited treatment options,patients with HCC have poor prognosis.It poses a serious threat to people's lives.Sorafenib is a small molecule multi-kinase inhibitor and is currently the only targeted drug approved for the treatment of advanced HCC.However,treatment failure often results from the development of treat⁃ment resistance.The development of HCC resistance to sorafenib therapy includes both primary and acquired,but the exact mechanism is not very clear.Therefore,it is particularly important to understand the mechanisms by which resistance to sorafenib therapy develops in HCC patients and to propose more effective therapeutic strategies.